Epithalon: A Research Overview

Introduction

Epithalon (also spelled Epitalon; chemical name Ala-Glu-Asp-Gly; CAS 307297-40-1) is a synthetic tetrapeptide derived from the amino-acid composition of Epithalamin, a polypeptide complex isolated from bovine pineal gland tissue. A 2025 narrative review published in the International Journal of Molecular Sciences characterized Epithalon as a compound with notable neuroendocrine and antioxidant properties in pre-clinical models [1]. The compound has accumulated more than four decades of published research, conducted primarily at the St. Petersburg Institute of Bioregulation and Gerontology, spanning in vitro, in vivo, and observational human studies. Research-grade Epithalon from SpartaLabs is verified by HPLC purity analysis and third-party testing for each production batch.

Background

The pineal gland (epiphysis cerebri) is an unpaired endocrine structure in the vertebrate brain that synthesizes and secretes melatonin in a light-entrained circadian pattern. Beyond melatonin, the gland produces a range of peptide compounds of ongoing scientific interest. Beginning in the early 1970s, a research program at what became the St. Petersburg Institute of Bioregulation and Gerontology — led by Vladimir Kh. Khavinson and Vladimir G. Morozov — investigated whether organ-derived polypeptide complexes could modulate aging-associated physiological changes in animal models [2].

That program first characterized a native bovine pineal extract designated Epithalamin. Subsequent analytical work, reported by Khavinson and colleagues in 2017, identified the tetrapeptide sequence Ala-Glu-Asp-Gly (AEDG) as present within the Epithalamin polypeptide complex and demonstrated that this short peptide was responsible for a significant portion of the complex's observed biological activity [3]. The synthetic version of AEDG was designated Epithalon (Epitalon) and became the principal research compound in subsequent publications.

Chemistry and Structure

Epithalon is a tetrapeptide consisting of four amino acid residues in the sequence: L-alanine – L-glutamic acid – L-aspartic acid – glycine (Ala-Glu-Asp-Gly). Its molecular formula is C14H22N4O9 and its molecular weight is approximately 390.3 daltons. The compound is water-soluble and is studied as either the free acid or acetate salt form.

The small size of the molecule — four residues — distinguishes it from the larger polypeptide parent extract Epithalamin and is consistent with the pharmacological concept of "short peptide bioregulators" developed within the Khavinson research program. In this framework, the shortest peptide fragment retaining the biological signal of a parent polypeptide is isolated and synthesized for defined experimental use, affording greater chemical precision and reproducibility.

The 2025 review by Araj and colleagues noted that the compactness of the AEDG sequence may facilitate interaction with nucleosomal histones, which has been proposed as a mechanism underlying its reported epigenetic activity in cell-based experiments [1].

Pharmacological Classification

Epithalon is classified in the primary literature as a pineal peptide bioregulator — a class of short synthetic peptides derived from tissue-specific polypeptide extracts originally characterized within Soviet and Russian gerontological research. Its reported activities involve modulation of chromatin accessibility, gene expression, and enzymatic function, particularly telomerase activity, in cell-culture models.

The compound belongs to the broader class of Khavinson peptides (also referred to as cytomaxes and cytogens in the primary Russian literature): short di-, tri-, or tetrapeptides derived from organ-specific polypeptide complexes. The pineal-gland origin distinguishes Epithalon from thymic-derived peptides (e.g., Vilon/Lys-Glu) or cerebral-derived peptides such as Pinealon within the same research family.

Cell-based studies have also examined the relationship between Epithalamin — the parent extract — and melatonin-related circadian rhythms in elderly subjects [4], establishing a neuroendocrine context for the research program from which Epithalon emerged.

Regulatory Status

Epithalon has no approved therapeutic indication from the United States Food and Drug Administration (FDA). The compound appeared on the FDA's Category 2 bulk substances list as a compound under consideration for potential compounding pharmacy use, pending renewed review — a status that acknowledges the existing body of published research while the regulatory process remains active.

Within Russia, the broader Khavinson bioregulator research program produced several peptide-based pharmaceuticals registered as medicines (Thymalin, Cortexin), establishing regulatory precedent for the peptide bioregulator class. Epithalon itself, as the synthetic tetrapeptide, has not achieved separate registered pharmaceutical status in Russia as of the reviewed literature.

The parent extract Epithalamin was studied in Russian clinical observational settings for several decades in elderly patient cohorts, contributing to the scientific foundation on which the synthetic compound's research record builds.

Discovery History

The history of Epithalon is inseparable from the broader history of peptide bioregulator research initiated in the Soviet Union in the early 1970s. Anisimov, Khavinson, and Morozov published a 1994 retrospective documenting twenty years of experimental work with Epithalamin in gerontological and oncological animal models [2], establishing an unusually long and detailed scientific lineage for the compound class.

The synthesis of the isolated tetrapeptide AEDG as a discrete research compound — Epithalon — represented a refinement of the parent extract approach. Formal analytical identification of AEDG within the Epithalamin complex was confirmed by selective reaction monitoring mass spectrometry and reported in the Bulletin of Experimental Biology and Medicine in 2017 [3]. The compound's foundational in vitro characterization for telomerase-related activity was published by Khavinson and colleagues in 2003 [5], with subsequent rodent lifetime studies and observational human cohort data extending the research record through the 2000s and 2010s. The telomerase and chromatin pathways proposed in those studies are covered in detail in the Epithalon mechanism of action article. As of 2025, independent research groups in Europe and the Middle East have begun contributing replication and extension studies, broadening the base of the published literature.

References

1. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. DOI: 10.3390/ijms26062691. PMCID: PMC11943447.

2. Anisimov VN, Khavinson VKh, Morozov VG. Twenty Years of Study on Effects of Pineal Peptide Preparation: Epithalamin in Experimental Gerontology and Oncology. Ann N Y Acad Sci. 1994;719:483–493. DOI: 10.1111/j.1749-6632.1994.tb56853.x.

3. Khavinson VKh, Kopylov AT, Vas'kovskiy BV, Ryzhak GA, Lin'kova NS. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med. 2017;164(3):308–310. DOI: 10.1007/s10517-017-3922-8. PMID: 29124531.

4. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Effect of Peptide Preparation Epithalamin on Circadian Rhythm of Epiphyseal Melatonin-Producing Function in Elderly People. Bull Exp Biol Med. 2004;137(4):389–391. DOI: 10.1023/B:BEBM.0000035139.31138.bf.

5. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bull Exp Biol Med. 2003;135(6):590–592. DOI: 10.1023/A:1025493705728. PMID: 12937682.